Drug Trial Radar · NCT03794544
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Mar 8, 2019
Primary completion
Jan 13, 2021
Study completion Jan 13, 2021
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 102 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I \[\>2cm\] to IIIA) non-small cell lung cancer (NSCLC).
Conditions
- Resectable
- Early-stage
- NSCLC
Interventions
DurvalumabDrug
Durvalumab 1500 mg IV will be administered Q4W (on Week 1 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
OleclumabCombination product
Oleclumab 3000 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
MonalizumabCombination product
Monalizumab 750 mg IV will be administered Q2W (on Week 1 Day 1 and Week 3 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
DanvatirsenCombination product
Danvatirsen 200 mg IV will be administered on Days 1, 3, and 5 of Week 0 (7-day danvatirsen lead-in period) and later every week (on Week 1 Day 1, Week 2 Day 1, Week 3 Day 1, and Week 4 Day 1) until disease progression, unacceptable toxicity, or other reason of treatment discontinuation over a 28-day treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Pathological Response RateTime frame: Day 1 through Day 42
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
La Jolla, California
Research Site
Fort Myers, Florida
Research Site
Leesburg, Florida
Research Site
Baltimore, Maryland
Research Site
Buffalo, New York
Research Site
New York, New York
Research Site
Chattanooga, Tennessee
Research Site
Nashville, Tennessee
Research Site
Houston, Texas
Research Site
Fairfax, Virginia
Research Site
Montreal, Quebec, Canada
Research Site
Marseille, France
Research Site
Toulouse, France
Research Site
Orbassano, Italy
Research Site
Porto, Portugal
Research Site
A Coruña, Spain
Research Site
Barcelona, Spain
Research Site
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.